Clinical trial
A Twenty-four Week, Randomized, Double-blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin (100 Milligrams) Administered Orally Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in the United States
NCT00996164 is registered in ClinicalTrials.gov with Sprout Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Twenty-four Week, Randomized, Double-blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin (100 Milligrams) Administered Orally Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in the United States
- Lead sponsor
- Sprout Pharmaceuticals, Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2009
- Completion date
- February 28, 2011
- Enrollment
- 1,090 (actual)
- Sites
- 75
Conditions
As the registry lists them; a condition with its own page is linked.